Literature DB >> 9631364

The contribution of 18F-fluoro-2-deoxy-glucose positron emission tomographic imaging to radiotherapy planning in lung cancer.

J D Kiffer1, S U Berlangieri, A M Scott, G Quong, M Feigen, W Schumer, C P Clarke, S R Knight, F J Daniel.   

Abstract

A retrospective analysis was performed to determine whether coronal thoracic [18F]fluoro-2-deoxy-glucose positron emission tomography (FDG-PET) scans, if viewed at the time of radiotherapy (RT) planning, would have influenced the anterior-posterior (AP) RT volumes that were administered to a group of unoperated lung cancer patients. Viewing of PET and diagnostic images enabled a qualitative assessment of whether abnormal thoracic PET activity was present in areas regarded as normal by diagnostic imaging; this would, therefore, have influenced the RT volume if done prospectively. Additionally a method of graphical co-registration was devised to quantitate the adequacy of coverage of each patient's abnormal PET activity by his/her actual RT field. Of 15 patients analyzed, 26.7% (four patients) would have had their RT volume influenced by PET findings, highlighting the potential value of PET in treatment planning.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9631364     DOI: 10.1016/s0169-5002(97)00086-x

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  22 in total

1.  Requirements for clinical PET: comparisons within Europe.

Authors:  Michael Bedford; Michael N Maisey
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-02       Impact factor: 9.236

2.  The role of molecular imaging in precision radiation therapy for target definition, treatment planning optimisation and quality control.

Authors:  Giovanni Lucignani; Barbara A Jereczek-Fossa; Roberto Orecchia
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-03-30       Impact factor: 9.236

Review 3.  PET-guided delineation of radiation therapy treatment volumes: a survey of image segmentation techniques.

Authors:  Habib Zaidi; Issam El Naqa
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-03-25       Impact factor: 9.236

4.  PET-CT in the staging and treatment of non-small-cell lung cancer.

Authors:  Patricia Ibeas; Blanca Cantos; José Manuel Gasent; Begoña Rodríguez; Mariano Provencio
Journal:  Clin Transl Oncol       Date:  2011-06       Impact factor: 3.405

5.  Computer-aided diagnosis systems for lung cancer: challenges and methodologies.

Authors:  Ayman El-Baz; Garth M Beache; Georgy Gimel'farb; Kenji Suzuki; Kazunori Okada; Ahmed Elnakib; Ahmed Soliman; Behnoush Abdollahi
Journal:  Int J Biomed Imaging       Date:  2013-01-29

6.  Radiotherapy planning: PET/CT scanner performances in the definition of gross tumour volume and clinical target volume.

Authors:  Ernesto Brianzoni; Gloria Rossi; Sergio Ancidei; Alfonso Berbellini; Francesca Capoccetti; Carla Cidda; Paola D'Avenia; Sara Fattori; Gian Carlo Montini; Gianluca Valentini; Alfredo Proietti; Carlo Algranati
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-08-26       Impact factor: 9.236

7.  Target volume definition for 18F-FDG PET-positive lymph nodes in radiotherapy of patients with non-small cell lung cancer.

Authors:  Ursula Nestle; Andrea Schaefer-Schuler; Stephanie Kremp; Andreas Groeschel; Dirk Hellwig; Christian Rübe; Carl-Martin Kirsch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-10-21       Impact factor: 9.236

Review 8.  The imaging of small pulmonary nodules.

Authors:  Zejun Zhou; Ping Zhan; Jiajia Jin; Yafang Liu; Qian Li; Chenhui Ma; Yingying Miao; Qingqing Zhu; Panwen Tian; Tangfeng Lv; Yong Song
Journal:  Transl Lung Cancer Res       Date:  2017-02

9.  Does pre-operative estimation of oesophageal tumour metabolic length using 18F-fluorodeoxyglucose PET/CT images compare with surgical pathology length?

Authors:  Reubendra Jeganathan; James McGuigan; Frederick Campbell; Thomas Lynch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-12-16       Impact factor: 9.236

Review 10.  18F-FDG PET/CT for image-guided and intensity-modulated radiotherapy.

Authors:  Eric C Ford; Joseph Herman; Ellen Yorke; Richard L Wahl
Journal:  J Nucl Med       Date:  2009-09-16       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.